Neuroprotective effects of (±)-Kavain in the MPTP mouse model of Parkinson's disease

Synapse

Volumn 40, Issue 1, 2001, Pages 47-54

  Schmidt, Nicole ^a   Ferger, Boris ^a,b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b ETH ZURICH   (Switzerland)

Author keywords

Dopamine; Excitotoxicity; Glutamate; Neurodegeneration; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; EXCITOTOXIN; GLUTAMIC ACID; KAWAIN; TYROSINE 3 MONOOXYGENASE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT; PYRONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ELECTROCHEMICAL ANALYSIS; IMMUNOCYTOCHEMISTRY; MALE; MOUSE; NEOSTRIATUM; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; ANIMAL; BRAIN; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; METABOLISM; NERVE CELL; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTICONVULSANTS; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; MALE; MICE; MICE, INBRED C57BL; NEOSTRIATUM; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PYRONES; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 0034745919     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2396(200104)40:1<47::AID-SYN1025>3.0.CO;2-S     Document Type: Article

References (38)

1. Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents
2. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats
3. Aging, energy and oxidative stress in neurodegenerative diseases
4. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model
5. Riluzole and experimental parkinsonism: Antagonism of MPTP-induced decrease in central dopamine levels in mice
6. In vivo effects of the kavapyrones (+)-dihydromethysticin and (±)-kavain on dopamine. 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxy-indoleacetic acid levels in striatal and cortical brain regions
7. +)
8. Oxidative stress, glutamate, and neurodegenerative disorders
9. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems
10. In vivo microdialysis study of (±)-kavain on veratridine-induced glutamate release
11. Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo
12. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice
13. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
14. (±)-Kavain inhibits veratridine-activated voltage-dependent Na(+)-channels in synaptosomes prepared from rat cerebral cortex
15. 2+ and glutamate-release of rat cerebrocortical synaptosomes
16. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes
17. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse: Relationships between monoamine oxidase, MPTP metabolism and neurotoxicity
18. Oxidative mechanisms in nigral cell death in Parkinson's disease
19. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys
20. Vergleichende untersuchungen über die antikonvulsive wirksamkeit der pyronverbindungen aus piper methysticum forst
21. Do NMDA receptor antagonists protect against MPTP toxicity? Biochemical and immunocytochemical analyses in black mice
22. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice
23. +): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra
24. Parkinson's disease research moves on briskly
25. Thalamic, subthalamic nucleus and internal pallidum stimulation in Parkinson's disease
26. The role of glutamate in epilepsy and other CNS disorders
27. Kawa-Pyrone, eine neuartige substanzgruppe zentraler muskelrelaxantien vom typ des merphenisins
28. Etiology and pathogenesis of Parkinson's disease
29. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis
30. - neurotoxicity by N-methyl-D-aspartate antagonists
31. Parkinson's disease: A major hypokinetic basal ganglia disorder
32. Cerebroprotective effect of lamotrigine after focal ischemia in rats
33. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic MPTP in mice or intranigral MPTP in rats
34. Advances in our understanding of the mechanism of the neurotoxicity of MPTP and related compounds
35. - neurotoxicity by N-methyl-D-aspartate antagonists
36. Inhibition of platelet MAO-B by kavapyrone-enriched extract from Piper methysticum Forster (kava-kava)
37. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia